Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Abstract 1790: PDJ amplicon heterogeneity in triple negative breast cancers
Malasi, Smriti, Lenkiewicz, Elizabeth, Pockaj, Barbara A. , Koslosky, Lori , Hartmayer, Peter, Anderson, Karen S. , Barrett, Michael T. , Roesler, Alexander S. , Lewis, Michael T. , Dobrolecki, Lacey E.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 1790-1790

10.1158/1538-7445.am2020-1790 Get It

Abstract Background: Amplification of chromosome 9p24.1 targeting PD-L1, PD-L2, and JAK2 (PDJ amplicon) is present in ~15% of TNBCs and is associated with activation of the JAK/STAT pathway and poor clinical outcomes. In preclinical studies, PD-L1 expression is markedly and rapidly inducible by low-dose IFN-γ in a PDJ amplicon copy-number dependent manner, mimicking an in situ inflammatory response. This suggests PDJ amplification could identify those TNBCs that would respond to ICIs and/or JAK2 targeted-therapies. The goals in this study were to determine the PDJ status of a well annotated cohort of TNBC PDXs with a 3 color FISH assay and to further define the genomes and transcriptomes of PDJ+ and PDJ- TNBCs. Methods: Tissue microarrays (TMAs) of 49 cores from 27 breast cancer PDX samples, including 21 TNBCs were obtained from the Baylor College of Medicine. The TMAs were interrogated with a 3 color FISH assay consisting of three probes that simultaneously target the PDJ amplicon, 9q22, and 9q34.1. The ratios of PDJ to 9q22 and PDJ to 9q34.1 were calculated to distinguish PDJ amplification from polyploidy. In each case, 50 cells were scored. Samples with PDJ signal >4.0, PDJ/9q22 ≥2 and/or PDJ/9q34.1 ≥2 were called positive by FISH. A subset of PDJ+ PDXs was then flow sorted by DNA content and interrogated with 400k whole genome CNV arrays. These results were integrated with existing clinical, exome, and transcriptome data for the TMAs (pdxportal.research.bcm.edu). Results: PDJ amplification was identified in 6/27 PDX samples including 3/21 (14%) TNBCs. Notably the number of PDJ+ cells in each sample ranged from 2-18. Single cells with ≥10 copies were observed in each PDJ+ sample as well as two PDJ- TNBCs. PDJ+ samples had increased expression of PD-L1 and JAK2 in their RNAseq data. Whole genome CNV analysis of flow sorted PDJ+ samples confirmed the presence of the PDJ amplicon and identified co-occurring amplifications and deletions. A similar pattern of PDJ amplicon heterogeneity was seen in a Mayo Clinic Arizona cohort of 70 surgically resected TNBCs. Previous whole genome CNV analysis of flow sorted samples identified 13/70 (18%) PDJ+ cases. FISH analysis of 14 TNBCs from this cohort (PDJ+ and PDJ- cases) validated these results and identified PDJ+ tumors with cells containing >20 copies of the amplicon. Conclusion: Our multicolor FISH assay of PDX and primary resected samples confirms a prevalence of ~15% PDJ+ TNBCs. Previous studies have reported an enrichment of JAK2 amplification in neoadjuvant treated TNBCs. Given the heterogeneous FISH patterns in both PDJ+ and PDJ- samples in our cohorts, we hypothesize that neoadjuvant therapy could enrich the presence of PDJ+ cells and thereby sensitize TNBCs to ICIs and JAK2 targeted therapies. Future work will explore the role of PDJ amplification and the presence of PDJ+ cells in TNBCs in response to neoadjuvant therapy. Citation Format: Alexander S. Roesler, Smriti Malasi, Elizabeth Lenkiewicz, Barbara A. Pockaj, Michael T. Lewis, Lacey E. Dobrolecki, Lori Koslosky, Peter Hartmayer, Karen S. Anderson, Michael T. Barrett. PDJ amplicon heterogeneity in triple negative breast cancers [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1790.
Reply to E. K. Bartlett et al and A. H. R. Varey et al
Bellomo, Domenico , Bridges, Alina G. , Meves, Alexander , Hieken, Tina J.

Mayo Clinic

JCO Precision Oncology | September 3, 2020 | Volume: No volume available | Issue: 4 | Pages: 992-994

10.1200/po.20.00289 | PMID 32914042 Get It

C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy
Cook, Casey , Wu, Yanwei , Odeh, Hana M. , Gendron, Tania F. , Jansen‐West, Karen , Rosso, Giulia del, Yue, Mei, Jiang, Peizhou , Gomes, Edward, Tong, Jimei, Daughrity, Lillian M. , Avendano, Nicole M., Castanedes‐Casey, Monica , Shao, Wei , Oskarsson, Björn , Tomassy, Giulio Srubek, McCampbell, Alexander , Rigo, Frank , Zhang, Yong‐Jie , Petrucelli, Leonard , Cook, Casey N , Del Rosso, Giulia, Dickson, Dennis W , Shorter, James , Zhang, Yong-Jie , Petrucelli, Leonard , Oskarsson, Björn , Gendron, Tania F , Shao, Wei , Dickson, Dennis W. , Shorter, James

Mayo Clinic

Science Translational Medicine | September 2, 2020 | Volume: 12 | Issue: 559 | Pages: No page available

10.1126/scitranslmed.abb3774 | PMID 32878979 Get It

G 4 C 2 repeat–derived poly(GR) plays a key role in mediating TDP-43 mislocalization and aggregation in vitro and in vivo.
Loss of MAGEL2 in Prader-Willi syndrome leads to decreased secretory granule and neuropeptide production
Victor, A. Kaitlyn , Klein, Jonathon, Tacer, Klementina Fon , Tai, Derek J.C. , Esch, Celine de , Nuttle, Alexander, Temirov, Jamshid, Burnett, Lisa C. , Rosenbaum, Michael , Zhang, Yiying , Moresco, James J. , Diedrich, Jolene K. , Tillman, Heather, Leibel, Rudolph L. , Talkowski, Michael E. , Billadeau, Daniel D. , Reiter, Lawrence T. , Potts, Patrick Ryan , Chen, Helen , Ding, Li, Yates, John R. , Sheppard, Heather

Mayo Clinic

JCI Insight | September 2, 2020 | Volume: 5 | Issue: 17 | Pages: No page available

10.1172/jci.insight.138576 | PMID 32879135 Get It

Prader-Willi syndrome (PWS) is a developmental disorder caused by loss of maternally imprinted genes on 15q11-q13, including melanoma antigen gene family member L2 ( MAGEL2 ). The clinical phenotypes of PWS suggest impaired hypothalamic neuroendocrine function; however, the exact cellular defects are unknown. Here, we report deficits in secretory granule (SG) abundance and bioactive neuropeptide production upon loss of MAGEL2 in humans and mice. Unbiased proteomic analysis of Magel2 p Δ /m+ mice revealed a reduction in components of SG in the hypothalamus that was confirmed in 2 PWS patient–derived neuronal cell models. Mechanistically, we show that proper endosomal trafficking by the MAGEL2-regulated WASH complex is required to prevent aberrant lysosomal degradation of SG proteins and reduction of mature SG abundance. Importantly, loss of MAGEL2 in mice, NGN2-induced neurons, and human patients led to reduced neuropeptide production. Thus, MAGEL2 plays an important role in hypothalamic neuroendocrine function, and cellular defects in this pathway may contribute to PWS disease etiology. Moreover, these findings suggest unanticipated approaches for therapeutic intervention.
Abstract PR05: A meta-analysis of genome-wide association study and eQTL analysis of multiple myeloma among African Americans
Du, Zhaohui , Weinhold, Niels , Song, Gregory, Rand, K.A., Hwang, Amie E. , Sheng, Xin , Hom, Victor, Pawlish, Karen , Peters, Edward , Mohrbacher, Ann, Stram, Alexander , Berndt, Sonja I. , Blot, William J. , Stevens, Victoria L. , Goodman, Phyllis J. , Hennis, Anselm , Nemesure, Barbara , Stanford, Janet L. , Witte, John S. , Signorello, Lisa B., John, Esther M. , Stroup, Antoinette M. , Zangari, Maurizio , Zheng, Wei , Hu, Jennifer J. , Carpten, John D. , Mehta, Jayesh, Wolf, Jeffrey L. , Martin, Thomas G. , Terebelo, Howard R. , Janakiraman, Nalini, Kolonel, Laurence N. , Auclair, Daniel , Vij, Ravi , Bernal‐Mizrachi, Leon , Zonder, Jeffrey A. , Huff, Carol Ann , Conti, David V. , Haiman, Christopher A. , John, Esther M , Zheng, Wei , Conti, David V , Berg, David Van Den , Ailawadhi, Sikander , Nooka, Ajay K. , Singhal, Seema , Bock, Cathryn Hufford , Stram, Alex , Casey, Graham , Kittles, Rick A. , Diver, W. Ryan , Klein, Eric A. , Rybicki, Benjamin A. , Bernstein, Leslie , Stephens, Owen , Rhee, Frits van , Olshan, Andrew F. , Ziegler, Regina G. , Nyante, Sarah J. , Ingles, Sue A. , Press, Michael F. , Chanock, Stephen Jacob , Colditz, Graham A. , Tomasson, Michael H. , Fiala, Mark A. , Anderson, Kenneth C. , Marchand, Loı̈c Le , Chiu, Brian C.‐H. , Ziv, Elad , Stram, Daniel O. , Morgan, Gareth J. , Lonial, Sagar , Orlowski, Robert Z. , Cozen, Wendy

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 1, 2020 | Volume: 29 | Issue: 6_Supplement_2 | Pages: PR05-PR05

10.1158/1538-7755.disp19-pr05 Get It

Abstract Background: Persons of African ancestry (AA) experience a 1.5-2-fold risk of multiple myeloma (MM) compared to persons of European ancestry (EA). We assembled a set of MM patients with self-reported AA in order to evaluate the contribution of genetics to etiology in this high-risk group. Methods: Here we present the results of a meta-analysis of two GWAS in 1,813 cases and 8,871 controls of AA. We also conducted an admixture mapping scan to identify risk alleles associated with local ancestry, fine-mapped the 23 known susceptibility loci to find markers that could better capture MM risk in individuals of AA, and constructed a polygenic risk score (PRS) to assess the aggregated effect of known MM risk alleles. Finally, we conducted an eQTL analysis measuring gene expression in those genes harboring a risk variant in malignant plasma cells from 292 of the patients from a single site. Results: In GWAS analysis, we identified two suggestive novel loci located at 9p24.3 and 9p13.1 at P<1 × 10-6, but no genome-wide significant association was noted. In admixture mapping, we observed a genome-wide significant inverse association between local AA at 2p24.1-23.1 and MM risk in AA individuals. 20 of the 23 known EA risk variants showed directional consistency and 9 replicated at P<0.05 in AA individuals. In eight regions, we identified markers that better capture MM risk in persons of AA. AA individuals with a PRS in the top 10% had a 1.82-fold (95%CI: 1.56, 2.11) increased MM risk compared to those with average risk (25-75%). The strongest functional association was between the risk allele for variant rs56219066 at 5q15 and lower ELL2 expression (P= 5.1 × 10–12). Conclusion: Our study shows that common genetic variation contributes to MM risk individuals of AA. This abstract is also being presented as Poster C040. Citation Format: Zhaohui Du, Niels Weinhold, Gregory Chi Song, Kristen A. Rand, David J. Van Den Berg, Amie E. Hwang, Xin Sheng, Victor Hom, Sikander Ailawadhi, Ajay K. Nooka, Seema Singhal, Karen Pawlish, Edward Peters, Cathryn Bock, Ann Mohrbacher, Alexander Stram, Sonja I. Berndt, William J. Blot, Graham Casey, Victoria L. Stevens, Rick Kittles, Phyllis J. Goodman, W. Ryan Diver, Anselm Hennis, Barbara Nemesure, Eric A. Klein, Benjamin A. Rybicki, Janet L. Stanford, John S. Witte, Lisa Signorello, Esther M. John, Leslie Bernstein, Antoinette Stroup, Owen W. Stephens, Maurizio Zangari, Frits Van Rhee, Andrew Olshan, Wei Zheng, Jennifer J. Hu, Regina Ziegler, Sarah J. Nyante, Sue Ann Ingles, Michael Press, John David Carpten, Stephen Chanock, Jayesh Mehta, Graham A Colditz, Jeffrey Wolf, Thomas G. Martin, Michael Tomasson, Mark A. Fiala, Howard Terebelo, Nalini Janakiraman, Laurence Kolonel, Kenneth C. Anderson, Loic Le Marchand, Daniel Auclair, Brian C.-H. Chiu, Elad Ziv, Daniel Stram, Ravi Vij, Leon Bernal-Mizrachi, Gareth J. Morgan, Jeffrey A. Zonder, Carol Ann Huff, Sagar Lonial, Robert Z. Orlowski, David V. Conti, Christopher A. Haiman, Wendy Cozen. A meta-analysis of genome-wide association study and eQTL analysis of multiple myeloma among African Americans [abstract]. In: Proceedings of the Twelfth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2019 Sep 20-23; San Francisco, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl_2):Abstract nr PR05.
Abstract IA02: DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response
Nesic, Kasenija, Hurley, Rachel M. , McGehee, Cordelia D. , Harrell, Maria I., Zapparoli, Giada V., Musafer, Ashan, Wong, Ming E., Weroha, S. John , Hou, Xiaonan , Negron, Vivian , Peterson, Kevin, Schneider, Paula A., Kondrashova, Olga , Li, Hu, Swisher, Elizabeth M. , Southey, Melissa C. , Dobrovic, Alexander , Wakefield, Matthew J. , Kaufmann, Scott H. , Scott, Clare L.

Mayo Clinic

Clinical Cancer Research | September 1, 2020 | Volume: 26 | Issue: 13_Supplement | Pages: IA02-IA02

10.1158/1557-3265.ovca19-ia02 Get It

Abstract PARP inhibitor (PARPi) resistance in high-grade serous ovarian carcinoma (HGSOC) can be acquired as a result of restored homologous recombination (HR) due to secondary or reversion mutations in HR genes, such as BRCA1, BRCA2, and RAD51C, or due to loss of BRCA1 promoter methylation (meBRCA1). We have demonstrated that homozygous meBRCA1 can be lost or reverted to heterozygous methylation following treatment with platinum-based chemotherapy, resulting in HR-competent PARPi-resistant tumors. RAD51C promoter methylation (meRAD51C) is detected in approximately 2% of HGSOC cases and, as with meBRCA1, is associated with gene silencing and HR deficiency. We are exploring PARPi response in meRAD51C preclinical models to determine clinical relevance. Two patient-derived xenograft (PDX) models of HGSOC with RAD51C gene silencing caused by meRAD51C have distinct meRAD51C profiles (measured by methylation-specific high-resolution melt analysis and targeted bisulfite next-generation sequencing), and different responses to PARPi treatment pressure. PDX PH039 loses methylation and regains RAD51C expression after only 2 cycles of PARPi retreatment (niraparib), resulting in PARPi-refractory tumors by cycle 3-4. Illumina EPIC methylation array analysis of PH039 revealed increasing global methylation losses following each round of PARPi treatment. Lack of meRAD51C stability and rapid development of PARPi resistance in PH039 may be due to the high degree of meRAD51C heterogeneity within the tumor favoring selection of pre-existing HR-competent clones under PARPi pressure. In contrast, PDX 183 has a relatively homogeneous and stable meRAD51C profile. We have multiple examples of using unique PDX models to demonstrate various important features of PARPi resistance, including loss of promoter methylation for BRCA1 vs. RAD51C. Thus, meRAD51C confers response to PARPi in HGSOC, but PARPi treatment pressure can cause loss of methylation and drug resistance in some tumors. The contrasting PARPi responses of these PDX provide a platform for the study of meRAD51C stability in vivo and may present therapeutic opportunities to improve meRAD51C durability and PARPi responses in patients. Citation Format: Kasenija Nesic, Rachel M Hurley, Cordelia McGehee, Olga Kondrashova, Maria I. Harrell, Giada V. Zapparoli, Ashan Musafer, Ming E. Wong, John Weroha, Xiaonan Hou, Hu Li, Vivian Negron, Kevin Peterson, Paula Schneider, Elizabeth M. Swisher, Melissa Southey, Alexander Dobrovic, Matthew Wakefield, Scott H. Kaufmann, Clare L. Scott. DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr IA02.
Aerosol Generation during Spirometry
Helgeson, Scott A. , Lee, Augustine S. , Niven, Alexander S. , Patel, Neal M. , Niven, Alexander S , Helgeson, Scott A , Lim, Kaiser G.

Mayo Clinic

Annals of the American Thoracic Society | September 1, 2020 | Volume: 17 | Issue: 12 | Pages: 1637-1639

10.1513/annalsats.202005-569rl | PMID 32870021 Get It

The multi-institutional myeloma group clinico-genomic risk stratification system: A blinded validation
Anguiano, A., Barry, William T., Gasparetto, Cristina, Shaughnessy, John D. , Potti, A., Tuchman, Sascha Alexander , Chng, Wee Joo , Zhan, Fenghuang , Gasparetto, Cristina , Fonseca, Rafaël

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 8521-8521

10.1200/jco.2009.27.15_suppl.8521 Get It

8521 Background: Several clinical and molecular prognostic factors (e.g, International Staging System [ISS] stage, plasma cell labeling index, genomic models) exist for multiple myeloma (MM). We hypothesized that exploiting gene signatures representative of oncogenic pathway deregulation (i.e., Ras, Myc, etc.), would improve MM prognostication and also aid with the identification of novel therapeutic targets. Methods: Using a discovery cohort (n=47) of patients with MM and corresponding gene expression data, we built upon current molecular risk-stratification and devised a Bayesian genomic (“metagene”) model for prognosis. We validated that model in an independent patient cohort (n=207). Finally, we incorporated ISS staging and clinical variables to construct a combined Clinico-Genomic Risk Stratification System. We further validated the combined model in a separate cohort (n=72), in a blinded manner. Results: Using gene signatures predictive of oncogenic pathway activation in the discovery cohort, we identified specific patterns (metagenes) of signaling pathway activation with prognostic relevance. In an independent validation cohort, this metagene-based model accurately predicted event free survival (EFS) independently of ISS (multivariate hazard ratio [HR] 3.4 for ISS stage, and 5.4 for the metagene model, p=0.002). Using multivariate risk modeling, we incorporated ISS staging and the metagene model into a Clinico-Genomic System and successfully stratified the validation cohort into three groups (low, intermediate, and high risk) with markedly different EFS (HR 4.2 for intermediate risk and 14.0 for high risk vs. the low risk cohort, p<0.0001). In an additional blinded validation, the Clinico-Genomic System again accurately predicted median overall survival (68.7 [low risk] vs 24.7 [intermediate risk] vs 18.7 months [high risk], p<0.0001); more accurately than either ISS or other reported genomic models. Conclusions: A combined Clinico-Genomic Risk Stratification System, building on patterns of oncogenic pathway activation and ISS staging system, improves upon current prognostic models in MM and identifies novel pathway targets for future therapeutic consideration. No significant financial relationships to disclose.
Rabgap1 promotes recycling of active β1 integrins to support effective cell migration
Samarelli, Anna Valeria, Meves, Alexander , Fässler, Reinhard , Böttcher, Ralph T. , Meves, Alexander , Böttcher, Ralph T , Ziegler, Tilman

Mayo Clinic

Journal of Cell Science | August 25, 2020 | Volume: 133 | Issue: 18 | Pages: No page available

10.1242/jcs.243683 | PMID 32843574 Get It

ABSTRACT Integrin function depends on the continuous internalization of integrins and their subsequent endosomal recycling to the plasma membrane to drive adhesion dynamics, cell migration and invasion. Here we assign a pivotal role for Rabgap1 (GAPCenA) in the recycling of endocytosed active β1 integrins to the plasma membrane. The phosphotyrosine-binding (PTB) domain of Rabgap1 binds to the membrane-proximal NPxY motif in the cytoplasmic domain of β1 integrin subunits on endosomes. Silencing Rabgap1 in mouse fibroblasts leads to the intracellular accumulation of active β1 integrins, alters focal adhesion formation, and decreases cell migration and cancer cell invasion. Functionally, Rabgap1 facilitates active β1 integrin recycling to the plasma membrane through attenuation of Rab11 activity. Taken together, our results identify Rabgap1 as an important factor for conformation-specific integrin trafficking and define the role of Rabgap1 in β1-integrin-mediated cell migration in mouse fibroblasts and breast cancer cells.
What Is the Difference in Cranial Base Morphology in Isolated and Syndromic Bicoronal Synostosis?
Lu, Xiaona , Forte, Antonio J. , Wilson, Alexander T. , Park, Kitae Eric , Allam, Omar , Mozaffari, Mohammad Ali , Alperovich, Michael , Steinbacher, Derek M., Alonso, Nivaldo , Persing, John A. , Forte, Antonio Jorge

Mayo Clinic

Plastic & Reconstructive Surgery | August 25, 2020 | Volume: 146 | Issue: 3 | Pages: 599-610

10.1097/prs.0000000000007068 | PMID 32842109 Get It

Background: The association of isolated craniosynostosis and the influence of syndromic forms confound the understanding of craniofacial morphologic development. This study attempts to clarify the individual influences of isolated bicoronal synostosis, Apert syndrome, and Crouzon syndromes on skull base morphology. Methods:: One hundred seventeen computed tomographic scans were included (nonsyndromic bicoronal synostosis, n = 36; Apert syndrome with bicoronal synostosis, n = 25; Crouzon syndrome with bicoronal synostosis, n = 11; controls, n = 45). Cephalometric measurements were analyzed using Materialise software. Results: Nonsyndromic bicoronal synostosis patients developed a shortened cranial base length, with a significantly shortened distance between nasion and sella (p = 0.005). The cranial base angles of nonsyndromic bicoronal synostosis in both the cranial side (N-S-BA) and facial side (N-SO-BA) increased significantly, by 17.04 degrees (p < 0.001) and 11.75 degrees (p < 0.001), respectively. However, both the N-S-BA and N-SO-BA angles of Apert syndrome and Crouzon syndrome were narrowed more than that of nonsyndromic bicoronal synostosis [by 12.11 degrees (p < 0.001) and 12.44 degrees (p < 0.001), respectively, in Apert syndrome; and by 11.66 degrees (p = 0.007) and 13.71 degrees (p = 0.007), respectively, in Crouzon syndrome]. However, there is no statistically significant difference of these two angles between Apert syndrome and Crouzon syndrome, when they were only associated with bicoronal synostosis. Contrary to the relatively normal subcranial space of nonsyndromic bicoronal synostosis, both Apert and Crouzon syndromes developed a reduced subcranial space. Conclusions: Isolated bicoronal synostosis resulted in a flattened cranial base, whereas Apert syndrome and Crouzon syndrome developed a normal cranial base angle when only associated with bicoronal synostosis. The syndromic skulls had additional significantly reduced subcranial space.